印度制药公司Bharat Biotech针对卫生条件差的地区,推出口服霍乱疫苗HILLCHOL(BBV131),以应对全球霍乱挑战。 Indian pharmaceutical company Bharat Biotech launches oral cholera vaccine HILLCHOL (BBV131) to address global cholera challenge, targeting regions with poor sanitation.
印度制药公司Bharat Biotech已推出新的口服霍乱疫苗HILLCHOL(BBV131),以应对全球霍乱挑战,特别是在卫生条件差的地区。 Bharat Biotech, an Indian pharmaceutical company, has launched HILLCHOL (BBV131), a new oral cholera vaccine, to address the global cholera challenge, particularly in regions with poor sanitation. 适合1岁以上个人使用的疫苗是根据希勒曼实验室颁发的许可证研制的,需要第0天和第14天使用。 The vaccine, suitable for individuals aged over one year, was developed under a license from Hilleman Laboratories and requires administration on day 0 and day 14. Bharat生物技术的生产能力为2亿剂量,旨在帮助缩小霍乱疫苗供应方面的全球差距,并促进霍乱控制问题全球工作队到2030年将霍乱相关死亡人数减少90%的目标。 With production capacity at 200 million doses, Bharat Biotech aims to help bridge the global gap in cholera vaccine supply and contribute to the Global Task Force on Cholera Control's goal of reducing cholera-related deaths by 90% by 2030.